-77%

est. 2Y upside i

HealthcareSeries A

Rank

#2979

Sector

Healthcare AI

Est. Liquidity

~4Y

Data Quality

Data: Medium

DeepScribe operates in a high-growth healthcare AI market with a strong value proposition and notable customer traction, particularly in oncology.

Last updated: March 10, 2026

Bull (25%)+200%

DeepScribe leverages its oncology leadership and strategic partnerships like Pearl Health to accelerate adoption across specialties, driving revenue to $100M+ by 2028 and justifying a $480M+ valuation at 4.8x revenue, a 200% upside.

Base (20%)+50%

DeepScribe continues to grow steadily within its niche, fending off competitors but facing pressure on market share. Revenue reaches ~$60M by 2028, leading to a $240M valuation, a 50% upside.

Bear (55%)-60%

Aggressive moves by Microsoft (Nuance) and well-funded competitors like Abridge and Suki AI erode DeepScribe's market share and pricing power, leading to slower growth and a down round. Valuation drops to $64M, representing a 60% downside for common shareholders.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

33%

Investors hold $61.2M in liquidation preferences, meaning common stock holders would receive nothing in an exit below $61.2M, and significantly diluted returns between $61.2M and $160.08M.

Dilution Risk

high

As a Series B company, DeepScribe will likely require additional funding rounds, leading to further dilution for current equity holders.

Secondary Liquidity

limited

While platforms like Hiive and EquityZen list DeepScribe shares, secondary liquidity is limited and typically for accredited investors, not guaranteed for employees.

View all 2 open roles at DeepScribe →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on DeepScribe's data — designed to show you've done your homework.

  • 1

    “How is DeepScribe strategically positioning itself to defend against the significant incumbent threat from Microsoft (Nuance) and other well-funded competitors like Abridge and Suki AI?”

  • 2

    “With strong momentum in oncology, what is the company's detailed playbook for expanding into other complex medical specialties or deepening penetration within existing customer segments to reach the broader $5.4B SAM?”

  • 3

    “Given the Series B funding round and the current valuation, what is the anticipated timeline for a liquidity event (e.g., IPO or acquisition) for employees, and how is the company managing potential future dilution for common shareholders?”

Community

Valuation Sentiment

Our model estimates -77% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.